Lisinopril — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Chronic Kidney Disease

• Amlodipine
• Atorvastatin
• Furosemide
• Losartan

Also listed for Coronary Artery Disease

• Aspirin
• Clopidogrel
• Metoprolol
• Nitroglycerin

Other medications in Heart & Cardiovascular

• Lovastatin
• Macitentan
• Metolazone
• Metoprolol Succinate
• Milrinone
• Moexipril
• Nadolol
• Nebivolol

About Lisinopril

Lisinopril is a widely prescribed medication crucial for managing high blood pressure and certain heart conditions. It helps millions lead healthier lives by improving cardiovascular function. With TheDrugClub, accessing this essential medication is not only easy but also incredibly affordable, ensuring you can prioritize your health without financial strain.

Lisinopril is a powerful angiotensin-converting enzyme (ACE) inhibitor, primarily prescribed to treat high blood pressure, also known as hypertension. Left untreated, high blood pressure can lead to serious health complications like heart attack, stroke, and kidney disease. Beyond hypertension, lisinopril is also a cornerstone in the management of heart failure, helping to improve symptoms and quality of life. Furthermore, it's often used to improve survival rates after a heart attack and can even be prescribed to protect kidney function in individuals with diabetes. Your doctor will determine if lisinopril is the right medication for your specific health needs.

At its core, l

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Lisinopril is approved for (FDA label)

Lisinopril tablets USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes.

Source: Read the full FDA label on DailyMed. Label effective date: September 10, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Lisinopril (FDA label)

WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue lisinopril as soon as possible. ( 5.1 ) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 ) WARNING: FETAL TOXICITY When pregnancy is detected, discontinue lisinopril as soon as possible [see WARNINGS AND PRECAUTIONS ( 5.1 )] . Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see WARNINGS AND PRECAUTIONS ( 5.1 )] .

Source: FDA prescribing information (DailyMed). Set ID: aa5d68e7-c2b9-41eb-ade4-2cd57edc1533. SPL document ID: 5b20e6c0-d339-c3bc-e063-6394a90a2d02. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Lisinopril (FDA label)

Tablets: 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg ( 3 ) 10 mg tablet is a pink coloured, round, biconvex, uncoated tablet with "LUPIN" debossed on one side and "10" on other side.

Source: FDA prescribing information (DailyMed). Set ID: aa5d68e7-c2b9-41eb-ade4-2cd57edc1533. SPL document ID: 5b20e6c0-d339-c3bc-e063-6394a90a2d02. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Lisinopril (FDA label)

Common adverse reactions (events 2% greater than placebo) by use: Hypertension: headache, dizziness and cough ( 6.1 ) Heart Failure: hypotension and chest pain ( 6.1 ) Acute Myocardial Infarction: hypotension ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Lupin Pharmaceuticals, Inc. at 1-800-399-2561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. Hypertension In clinical trials in patients with hypertension treated with lisinopril, 5.7% of patients on lisinopril discontinued with adverse reactions.

Source: FDA prescribing information (DailyMed). Set ID: aa5d68e7-c2b9-41eb-ade4-2cd57edc1533. SPL document ID: 5b20e6c0-d339-c3bc-e063-6394a90a2d02. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Lisinopril (FDA label)

Angioedema or a history of hereditary or idiopathic angioedema ( 4 ) Hypersensitivity ( 4 ) Co-administration of aliskiren with lisinopril in patients with diabetes ( 4 , 7.4 ) Lisinopril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Lisinopril tablet USP within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see WARNINGS AND PRECAUTIONS (5.2)] Lisinopril is contraindicated in patients with: a history of angioedema or hypersensitivity related to previous treatment with an angiotensin converting enzyme inhibitor hereditary or idiopathic angioedema Do not co-administer aliskiren with lisinopril in patients with diabetes [see DRUG INTERACTIONS ( 7.4 )]

Source: FDA prescribing information (DailyMed). Set ID: aa5d68e7-c2b9-41eb-ade4-2cd57edc1533. SPL document ID: 5b20e6c0-d339-c3bc-e063-6394a90a2d02. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Lisinopril (FDA label)

Angioedema: Discontinue lisinopril, provide appropriate therapy and monitor until resolved ( 5.2 ) Renal impairment: Monitor renal function periodically ( 5.3 ) Hypotension: Patients with other heart or renal diseases have increased risk, monitor blood pressure after initiation ( 5.4) Hyperkalemia: Monitor serum potassium periodically ( 5.5 ) Cholestatic jaundice and hepatic failure: Monitor for jaundice or signs of liver failure ( 5.6 ) 5.1 Fetal Toxicity Lisinopril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

Source: FDA prescribing information (DailyMed). Set ID: aa5d68e7-c2b9-41eb-ade4-2cd57edc1533. SPL document ID: 5b20e6c0-d339-c3bc-e063-6394a90a2d02. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Lisinopril (FDA label)

Diuretics: Excessive drop in blood pressure ( 7.1 ) NSAIDS: Increased risk of renal impairment and loss of antihypertensive efficacy ( 7.3 ) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension and hyperkalemia ( 7.4 ) Lithium: Symptoms of lithium toxicity ( 7.5 ) Gold: Nitritoid reactions have been reported ( 7.6 ) Concomitant mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7, 7.8) 7.1 Diuretics Initiation of lisinopril in patients on diuretics may result in excessive reduction of blood pressure. The possibility of hypotensive effects with lisinopril can be minimized by either decreasing or discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril.

Source: FDA prescribing information (DailyMed). Set ID: aa5d68e7-c2b9-41eb-ade4-2cd57edc1533. SPL document ID: 5b20e6c0-d339-c3bc-e063-6394a90a2d02. Label effective date: September 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.